Basic Information
| LncRNA/CircRNA Name | TDRG1 |
| Synonyms | NA |
| Region | GRCh38_6:40334954-40379887 |
| Ensemble | ENSG00000204091 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, in vitro knockdown, RIP |
| Sample | endometrial cancer tissues, cell lines (HEC-1B and Ishikawa) |
| Expression Pattern | up-regulated |
| Function Description | TDRG1 was significantly overexpressed in endometrial carcinoma tissues. Overexpression of lncRNA TDRG1 promoted endometrial carcinoma cell viability, invasion and migratory ability, inhibited apoptosis, and upregulated VEGF-A, PI3K, Bcl-2, MMP2 and survivin; knockdown of lncRNA TDRG1 had the opposite effects. LncRNA TDRG1 overexpression increased tumorigenicity in vivo and was associated with the upregulation of VEGF-A. RNA binding protein immunoprecipitation (RIP) assays confirmed that lncRNA TDRG1 directly binds to VEGF-A protein. Furthermore, knockdown of VEGFA in lncRNA TDRG1-overexpressing endometrial carcinoma cells reversed the effects of lncRNA TDRG1 on cell proliferation, invasion, migration and apoptosis. |
| Pubmed ID | 29920344 |
| Year | 2018 |
| Title | LncRNA TDRG1 Enhances Tumorigenicity in Endometrial Carcinoma by Binding and Targeting VEGF-A Protein |
External Links
| Links for TDRG1 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |